(Total Views: 752)
Posted On: 10/28/2020 10:27:47 AM
Post# of 145875
Quote:
LLY's MAB targets viral proteins and trial for critical patients has been stopped due to no perceived / observed benefit. This will happen to every MAB targeting viral spike proteins eventually, as mutations reduce binding site affinity.
While I agree viral mutations are a threat to all viral targeting MABs, I think the primary reason therapeutics like these won't help severe/critical populations (as opposed to LL) is because at that stage, the disease is more about immune disfunction rather than viral infection, as the good Dr. P reported several months ago.
That said, these MABs might offer significant benefit if administered very early in the infection cycle - IF you can figure out which patients were just infected. That's the rub.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)